February 23-24, 2023
This symposium is a clinical education experience for members of multidisciplinary teams who care for patients with rare, complex neuromuscular diseases including hereditary muscular dystrophies, motor neuron diseases, neuroimmunologic neuropathies and rare genetic disorders of muscle and nerve. Case presentations will include physical diagnosis and discussion of management and new therapies by participating experts. All discussions involve active participation by attendees. The educational format for this activity includes didactic lectures with in depth Q&A, panel discussions, and PowerPoint Presentations. The content of the program is identified and developed through a Call for Abstracts process and is specifically designed for Primary Care providers, Neurologists, NPs, PAs, and RNs that desire to gain advanced knowledge in diagnosis and management of patients with neuromuscular disease. The 2023 keynote speaker will present on the current advancements in congenital myopathies and muscular dystrophies.
Click HERE to view the Agenda!
This conference is scheduled to take place in-person. Live-stream and/or Hybrid options will not be available.
Registration Type:
| Registration Type | Before 1/13/23 | After 1/13/23 |
|---|---|---|
| Physicians | $100 | $150 |
| Fellows/Residents/Medical Students | $0 | $50 |
| Advanced Practice Providers (PA/NP)/Nurses | $0 | $50 |
| Other Healthcare Providers (OT/PT, SPL, Research Coordinators) | $0 | $50 |
| Exhibit/Industry Representative | $150 | $200 |
Interested in Exhibiting? Please send an email to CMERegistrations@UTSouthwestern.edu and request a copy of the Exhibitor Prospectus for this activity.
We are proud to announce that the 2023 Keynote Speaker is:
Jim Dowling, M.D., Ph.D.
Mogford Campbell Family Chair of Paediatric Neurosciences Staff clinician, Division of Neurology
Senior Scientist, Program for Genetics and Genome Biology Hospital for Sick Children
Professor, Departments of Paediatrics and Molecular Genetics University of Toronto
TARGET AUDIENCE
The content of the program is specifically designed for Primary Care providers, Neurologists, NPs, PAs, and RNs that desire to gain advanced knowledge in diagnosis and management of patients with neuromuscular disease.
LEARNING OBJECTIVES
- Discuss the principles and challenges of drug development for ultra-rare congenital muscular dystrophies and congenital myopathies.
- Discuss recent advances in the genetic diagnosis of neuromuscular disorders, in research and clinical practice and the latest developments in treatment such as gene replacement therapy.
- Identify and apply current pharmacological and non-pharmacological treatments in motor neuron diseases including gene replacement therapy.
- Recognize the clinical applications of testing in neuromuscular disorders (to include histopathology).